{"denomUnitsSelected":"Participants","description":"Rate of IL-6 antagonist","reportingStatus":"NOT_POSTED","timeFrame":"Baseline through Month 24","title":"Phase 2: Evaluate Efficacy Endpoints (IL-6)","type":"SECONDARY"}